Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

can identify which patients may benefit from 400IU of natural vitamin E. Administration of this dose and type of vitamin E led to a 50% reduction in non-fatal myocardial infarction in the ICARE study, reported earlier this year. The test is being developed to be used on current ubiquitous laboratory platforms (e.g., ELISA), and also to be used in genetic testing labs. The test is also being developed such that it will apply to CMS parameters for reimbursement. Once available, the Company plans to distribute the test to hospitals and other independent labs that have high volume customers.

To bring the most effective therapy to patients who will benefit most, Synvista has developed an extensive intellectual property portfolio based on utilizing haptoglobin genotyping or phenotyping to target the use of drugs in diabetic individuals with the Hp 2-2 genotype, thereby creating an unique product portfolio that both identifies a specific patient profile and provides therapeutic solutions to address patients' needs.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing marke
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film interference, ... demonstrated the ability to "paint" ultra-thin coatings onto ... for making future, flexible electronic devices, creating advanced ... rocket ships and spacecraft with extremely lightweight decorative ... water, it becomes iridescent, revealing a myriad of ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... used to kill nematodes. Nematodes are microscopic parasitic ... soil, water, and inside other plants and animals. ... high volatility or other properties promoting migration through ... contain more than 1,000 plant-parasitic nematodes. With more ...
Breaking Biology Technology:Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Canada, Oct. 14 ProtoKinetix (OTC,Bulletin Board: ... research,development and commercialization of patented anti-aging glycopeptides,(AAGPs(TM)), ... OTC Financial,Network (OTCFN), a division of National ... shareholder awareness campaign., "ProtoKinetix, AAGP(TM) platform ...
... SOMERSET, N.J., Oct. 14 Alfacell Corporation,(Nasdaq: ACEL ... quarter,and fiscal year ended July 31, 2008., The ... or $0.06,per basic and diluted common share, for the ... loss of approximately $2.4 million, or $0.05 per,basic and ...
... and Company,(NYSE: LLY ) announced today that its ... for all outstanding,shares of ImClone Systems Incorporated (Nasdaq: ... in cash. Lilly and ImClone previously announced that they ... ImClone., The Board of Directors of ImClone has ...
Cached Biology Technology:ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 2Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 4Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 5Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 2Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 3Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share 4
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
(Date:9/30/2014)... urban and farm runoff in Hawaii is causing tumors ... , The study, published Tuesday in the peer-reviewed open-access ... runoff ends up in algae that the turtles eat, ... flippers and internal organs. , Scientists at Duke University, ... Atmospheric Administration (NOAA) conducted the study to better understand ...
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... A new study led by scientists at the ... and Policy and the Rosenstiel School of Marine and ... respond to stress from catch-and-release fishing. The results revealed ... sharks were by far the most vulnerable to fighting ...
... study published in Cell by the teams ... in Biomedicine (IRB Barcelona) and the Institute of Molecular ... at the University of Wageningen, in the Netherlands, unravels ... activate multiple vital plant functions through various gene transcription ...
... say they have opened the window on the natural process of ... could be used to advance therapies for bone fractures and disease. ... the Feb. 13 issue of the journal Cell Reports , ... to allow adult zebra fish to perfectly replace bones lost upon ...
Cached Biology News:New study examines the effects of catch-and-release fishing on sharks 2Scientists unveil a molecular mechanism that controls plant growth and development 2Zebra fish fins help Oregon researchers gain insight into bone regeneration 2
... Certify products ATP-Free using Mo Bio ... sensitive ATP-Free certification service that will allow you ... level of accuracy and enable you to deliver ... Mo Bios ATP detection limit is 3.5 ...
... Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, Canada) ... have collaborated to develop a fluorescence reader ... The DNAscope AT is based on BPIs ... automatically reads up to six ArrayTubes in ...
... a comprehensive kinase analysis service utilizing ... peptide microarrays synthesized on Paraflo microfluidic ... quantitative measurement of kinase kinetic activities, ... service includes preparation of your kinase ...
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
Biology Products: